Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

β-Blockers in hypertension: studies and meta-analyses over the years.

Larochelle P, Tobe SW, Lacourcière Y.

Can J Cardiol. 2014 May;30(5 Suppl):S16-22. doi: 10.1016/j.cjca.2014.02.012. Epub 2014 Feb 25. Review.

2.

Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.

Calhoun DA, Lacourcière Y, Crikelair N, Jia Y, Glazer RD.

Curr Med Res Opin. 2013 Aug;29(8):901-10. doi: 10.1185/03007995.2013.803057. Epub 2013 Jul 1.

3.

Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.

Lacourcière Y.

Clin Exp Hypertens. 2013;35(1):50-60. doi: 10.3109/10641963.2012.690468. Epub 2012 Aug 6. Review.

PMID:
22866964
4.

Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.

Lacourcière Y, Taddei S, Konis G, Fang H, Severin T, Zhang J.

J Hypertens. 2012 Oct;30(10):2047-55. doi: 10.1097/HJH.0b013e328356b8ea.

PMID:
22828090
5.

The evolving role of β-adrenergic receptor blockers in managing hypertension.

Poirier L, Lacourcière Y.

Can J Cardiol. 2012 May;28(3):334-40. doi: 10.1016/j.cjca.2012.04.001. Review.

PMID:
22595449
6.
7.

24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.

Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA.

J Hum Hypertens. 2011 Oct;25(10):615-22. doi: 10.1038/jhh.2010.115. Epub 2011 Jan 20.

8.

24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study.

Wright JT Jr, Lacourcière Y, Samuel R, Zappe D, Purkayastha D, Black HR.

J Clin Hypertens (Greenwich). 2010 Nov;12(11):833-40. doi: 10.1111/j.1751-7176.2010.00372.x. Epub 2010 Sep 24.

9.
10.

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP.

Lancet. 2010 Apr 10;375(9722):1255-66. doi: 10.1016/S0140-6736(09)61966-8. Epub 2010 Mar 16.

PMID:
20236700
11.

Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction.

Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B; Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators.

Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7.

PMID:
19996069
12.

Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.

Lacourcière Y, Poirier L, Samuel R.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1491-501. doi: 10.1586/erc.09.140. Review.

PMID:
19954310
13.

Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.

Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD.

Hypertension. 2009 Jul;54(1):32-9. doi: 10.1161/HYPERTENSIONAHA.109.131300. Epub 2009 May 26.

PMID:
19470877
14.

Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.

Lacourcière Y, Wright JT Jr, Samuel R, Zappe D, Purkayastha D, Black HR; EVALUATE study.

Blood Press Monit. 2009 Jun;14(3):112-20. doi: 10.1097/MBP.0b013e32832a9da7.

PMID:
19384192
15.

Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.

Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM.

J Hum Hypertens. 2009 Sep;23(9):610-9. doi: 10.1038/jhh.2009.4. Epub 2009 Feb 19.

PMID:
19225530
16.
17.

Magnitude of the early morning blood pressure surge in untreated hypertensive patients: a pooled analysis.

Neutel JM, Schumacher H, Gosse P, Lacourcière Y, Williams B.

Int J Clin Pract. 2008 Nov;62(11):1654-63. doi: 10.1111/j.1742-1241.2008.01892.x. Epub 2008 Sep 15.

PMID:
18795972
18.

Aortic diameter, wall stiffness, and wave reflection in systolic hypertension.

Mitchell GF, Conlin PR, Dunlap ME, Lacourcière Y, Arnold JM, Ogilvie RI, Neutel J, Izzo JL Jr, Pfeffer MA.

Hypertension. 2008 Jan;51(1):105-11. Epub 2007 Dec 10.

PMID:
18071054
19.
20.
21.

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.

Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators.

Lancet. 2007 Jun 23;369(9579):2079-87.

PMID:
17586303
22.

Augmentation index and central aortic stiffness in middle-aged to elderly individuals.

Vyas M, Izzo JL Jr, Lacourcière Y, Arnold JM, Dunlap ME, Amato JL, Pfeffer MA, Mitchell GF.

Am J Hypertens. 2007 Jun;20(6):642-7.

PMID:
17531921
23.

The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.

Gosse P, Neutel JM, Schumacher H, Lacourcière Y, Williams B, Davidai G.

Blood Press Monit. 2007 Jun;12(3):141-7.

PMID:
17496463
25.

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y.

Br J Clin Pharmacol. 2007 May;63(5):575-82. Epub 2006 Nov 10.

27.
29.

Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition.

Mitchell GF, Lacourcière Y, Arnold JM, Dunlap ME, Conlin PR, Izzo JL Jr.

Hypertension. 2005 Nov;46(5):1111-7. Epub 2005 Oct 17.

PMID:
16230523
31.

Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.

Karas M, Lacourcière Y, LeBlanc AR, Nadeau R, Dubé B, Florescu M, Lamarre-Cliche M, Poirier L, Larochelle P, de Champlain J.

J Hypertens. 2005 Jun;23(6):1251-60.

PMID:
15894902
32.

Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, Grimm RH Jr, Hansson L, Lacourcière Y, Muller JE, Sleight P, Weber MA, White WB, Williams GH, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group.

J Hypertens. 2005 May;23(5):1099-106.

PMID:
15834298
33.

Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.

Lamarre-Cliche M, de Champlain J, Lacourcière Y, Poirier L, Karas M, Larochelle P.

Am J Hypertens. 2005 Jan;18(1):56-64.

PMID:
15691618
34.

A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.

Poirier L, de Champlain J, Larochelle P, Lamarre-Cliche M, Lacourcière Y.

Blood Press Monit. 2004 Oct;9(5):231-6.

PMID:
15472494
35.

Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.

White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS.

Am Heart J. 2004 Oct;148(4):628-34.

PMID:
15459593
36.

Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.

White WB, Lacourciere Y.

J Hypertens. 2004 Oct;22(10):2035-6; author reply 2036-8. No abstract available.

PMID:
15361777
37.

Sustained antihypertensive activity of telmisartan compared with valsartan.

Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H.

Blood Press Monit. 2004 Aug;9(4):203-10.

PMID:
15311147
38.

Effects of perindopril on elastic and structural properties of large arteries in essential hypertension.

Lacourcière Y, Béliveau R, Conter HS, Burgess ED, Lepage S, Pesant Y, Spence JD, Asmar R, Carrière S, Plante GE; Canadian Hypertension Society.

Can J Cardiol. 2004 Jun;20(8):795-9.

PMID:
15229761
41.

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.

Burgess ED, Lacourcière Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C.

Clin Ther. 2003 Sep;25(9):2388-404.

PMID:
14604739
42.

Effects of intense and prolonged exercise on insulin sensitivity and glycogen metabolism in hypertensive subjects.

Rhéaume C, Waib PH, Kouamé N, Nadeau A, Lacourcière Y, Joanisse DR, Simoneau JA, Cléroux J.

Circulation. 2003 Nov 25;108(21):2653-9. Epub 2003 Oct 27.

PMID:
14581404
43.

Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship.

Mitchell GF, Lacourcière Y, Ouellet JP, Izzo JL Jr, Neutel J, Kerwin LJ, Block AJ, Pfeffer MA.

Circulation. 2003 Sep 30;108(13):1592-8. Epub 2003 Sep 15.

PMID:
12975261
44.

Does QTc interval predict the response to beta-blockers and calcium channel blockers in hypertensives?

Lamarre-Cliche M, Lacourcière Y, de Champlain J, Poirier L, Larochelle P.

Heart Dis. 2003 Jul-Aug;5(4):244-52.

PMID:
12877758
45.
46.

Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension.

Lacourcière Y, Gil-Extremera B, Mueller O, Byrne M, Williams L.

Int J Clin Pract. 2003 May;57(4):273-9.

PMID:
12800457
47.

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCE Research Group.

JAMA. 2003 Apr 23-30;289(16):2073-82.

PMID:
12709465
48.

Economic impact of an ultrasonographic contrast agent on the diagnosis and initial management of patients with suspected renal artery stenosis.

Lévesque J, Lacourcière Y, Onrot JM, Wilson SR, Szaky E, Thibodeau M, Vasilevsky ML, Dashefsky SM, Allan DR, Lafortune M, Vendeville B, Zaleski WM, Pagé DE, D'Onofrio F.

Can Assoc Radiol J. 2002 Oct;53(4):228-36.

PMID:
12391929
49.

Impact of Levovist ultrasonographic contrast agent on the diagnosis and management of hypertensive patients with suspected renal artery stenosis: a Canadian multicentre pilot study.

Lacourcière Y, Lévesque J, Onrot JM, Wilson SR, Szaky E, Thibodeau M, Vasilevsky ML, Dashefsky SM, Allan DR, Lafortune M, Vendeville B, Zaleski WM, Pagé DE, D'Onofrio F.

Can Assoc Radiol J. 2002 Oct;53(4):219-27.

PMID:
12391928
50.

A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide.

Lacourcière Y.

J Int Med Res. 2002 Jul-Aug;30(4):366-79. Review.

PMID:
12235918

Supplemental Content

Loading ...
Support Center